Our History
  • During the initial stages of the HIV/AIDS epidemic, Government of Uganda reached out to Cipla Ltd of India urging them to partner with a local firm, Quality Chemicals Ltd (QCL), to enable Uganda to locally manufacture drugs to meet the challenges of treating HIV patients.
  • This was premised on the fact that over 60% of HIV/AIDS and 80% of malaria cases were in Sub-Saharan Africa yet the region only manufactured ¬†1% of its required medicines.
  • Also of concern was that the WTO Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement barred many developed pharmaceutical manufacturing countries like India from supplying medications still under patent at an affordable price. This posed a great threat for access to lifesaving medications for poor countries like Uganda.
  • However, the TRIPS agreement provided for a flexibility which allowed Least Developed Countries like Uganda to set up pharmaceutical facilities and manufacture medicines that were still under patent.
  • QCL took advantage of this flexibility and founded CiplaQCIL which ¬†today is approved by WHO and manufactures antiretroviral, antimalarial and hepatitis medicines.